Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

Abstract

Aim To explore the effect of TEC chemotherapy regimen (Docetaxel + Epirubicin + Cyclophosphamide) on traditional cardiovascular risk factors, atherosclerotic cardiovascular disease and cardiac electrical activity. Design 243 patients with first initially diagnosed breast cancer were collected who receiving TEC chemotherapy. Methods Univariate analysis, multivariate analysis, binary logistic regression analysis and statistical description were used to analyse the data. Results Among the first diagnosed patients, prevalence of hypertension and overweight/obesity in postmenopausal patients were significantly higher than premenopausal group. Compared with initially diagnosed state, incidence of hyperlipidaemia increased significantly after TEC chemotherapy, blood glucose level was remarkably increased, and prevalence of hyperuricaemia was significantly increased, changes of blood pressure level and prevalence rate of hypertension were not significant, and there was no statistical difference. Different menopause status showed the same trend. Atherosclerotic cardiovascular disease risk stratification showed after chemotherapy low‐risk patients decrease, medium‐risk and high‐risk people increased. Grouped by menstrual status, after chemotherapy, both groups showed the same trend. The independent influencing factors of increased heart rate after chemotherapy were postmenopausal status. Postmenopausal patients had more cardiovascular risk factors than premenopausal patients. After receiving chemotherapy, levels of cardiovascular risk factors in both groups mostly changed to the direction of disease. Chemotherapy drugs increase the risk of atherosclerotic cardiovascular disease in breast cancer patients. It is necessary to strengthen interdisciplinary cooperation to dynamic assess the cardiovascular health of patients of breast cancer patients.

Coronary atherosclerosis and chemotherapy: From bench to bedside

“…In another study, 243 patients with newly diagnosed breast cancer received anthracycline and other drugs (Table 1). After chemotherapy, the incidence of hyperlipidemia, level of blood glucose, and prevalence of hyperuricemia was significantly increased, and five patients (2.1%) were diagnosed 10.3389/fcvm.2023.1118002 with coronary artery disease (21). A recent clinical study showed significant increases in the mean carotid intima-media thickness and plaque score in 32 patients who received R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) for malignant B-cell lymphoma.…”

Effect of exercise on rehabilitation of breast cancer surgery patients: A systematic review and meta‐analysis of randomized controlled trials

“…Radical surgery (Bogach et al, 2022) supplemented by chemotherapy, radiotherapy, endocrine therapy and other therapies (Bhat et al, 2022; Dong et al, 2022; Wang et al, 2020) is the main treatment for BC. Radical surgery for BC primarily includes BC standard radical surgery (Halsted surgery), BC modified radical surgery, simple mastectomy, breast‐conserving surgery, axillary lymph node dissection and sentinel lymph node biopsy (Grebić et al, 2021).…”

“…The overall 5-year survival rates of stage I, II and III patients were 98%, 92% and 75% respectively (DeSantis et al, 2019). Therefore, the number of breast cancer survivors will continue to increase.Radical surgery (Bogach et al, 2022) supplemented by chemotherapy, radiotherapy, endocrine therapy and other therapies (Bhat et al, 2022;Dong et al, 2022;Wang et al, 2020) is the main treatment for BC. Radical surgery for BC primarily includes BC standard radical surgery (Halsted surgery), BC modified radical surgery, simple mastectomy, breast-conserving surgery, axillary lymph node dissection…”